In the history of modern medicine, few drugs have achieved what statins have. They are among the most prescribed medications on earth. In the United States alone, more than 40 million people take them daily. The revenues generated by the statin category over the past three decades are measured in hundreds of billions of dollars.
The story of how we arrived here is not simply a story of scientific progress. It is also a story of industry influence, of the selective presentation of data, of guideline committees with conflicts of interest, and of a clinical culture that has systematically deprioritised the conversation that the evidence most strongly supports: lifestyle.
The Number Nobody Tells You: NNT
When a drug’s benefits are communicated to patients — and in most cases they are not communicated at all, simply prescribed — they are almost invariably expressed in terms of relative risk reduction. “Statins reduce your risk of heart attack by 36%.” That number sounds substantial. It is also, in isolation, essentially meaningless without knowing the baseline risk from which that 36% is calculated.
The more honest measure is the Number Needed to Treat, or NNT. This tells you how many people must take the drug for a defined period for one person to benefit. For statins in primary prevention — the largest population of statin users, people with elevated cholesterol but no established heart disease — the NNT ranges from approximately 100 to 300 over five years. That means that for every 100 to 300 people taking a daily statin for five years, 99 to 299 of them receive no cardiovascular benefit.
The Cochrane Collaboration — one of the most rigorous independent evidence review bodies in medicine — published a systematic review of statins for primary prevention concluding that the evidence does not unambiguously support routine prescribing for people without established cardiovascular disease. That review has not received anywhere near the attention of the industry-funded trials that underpin current prescribing volumes.
What Patients Are Not Told: The Risk Profile
Every medication carries risks. The ethical practice of medicine requires that those risks be communicated honestly. In the case of statins, several are systematically under-communicated.
The CoQ10 Problem. Statins work by inhibiting HMG-CoA reductase — an enzyme in the mevalonate pathway. This pathway does not only produce cholesterol. It also produces coenzyme Q10, a molecule essential to mitochondrial energy production and present in high concentrations in cardiac muscle. When statins deplete CoQ10, patients may experience muscle fatigue, weakness, and pain — the most commonly reported statin side effect. There is also a genuine question about long-term cardiac implications of CoQ10 depletion in the very organ statins are intended to protect.
New-Onset Diabetes. In 2012, the FDA added a warning to all statin labels regarding the risk of new-onset Type 2 diabetes. The risk increase of approximately 10–12% is not trivial in a population already at metabolic risk — and Type 2 diabetes is itself a major cardiovascular risk factor. The drug prescribed to reduce cardiovascular risk may, in some patients, be increasing one of the primary drivers of that risk.
The Financial Architecture of Statin Dominance
Understanding how statins came to occupy their current position requires understanding the financial environment in which the evidence was generated and the guidelines were written. Industry-funded statin trials have been shown to be significantly more likely to report favourable outcomes than independently funded studies. Trials funded by manufacturers are more likely to be published when they show positive results and more likely to be stopped early when interim results look favourable — a statistical manoeuvre that tends to exaggerate apparent benefit.
The clinical guidelines that determine who gets prescribed a statin — published by bodies such as the American College of Cardiology and the American Heart Association — are written by committees of experts. A 2014 analysis found that the majority of authors of the ACC/AHA cholesterol guidelines had financial relationships with pharmaceutical companies. This does not mean the guidelines are wrong. It does mean the process that produced them is not independent.
The Prescription That Is Almost Never Written: Lifestyle
If a patient presents with elevated LDL cholesterol and no established cardiovascular disease, what should happen next? The evidence-based answer — supported by decades of research — is a structured, sustained conversation about lifestyle.
The PREDIMED trial demonstrated that a Mediterranean dietary pattern reduced major cardiovascular events by approximately 30% — a benefit comparable to or exceeding that of statin therapy in primary prevention, with no side effects and substantial additional health benefits. Resistance training improves insulin sensitivity, raises HDL, shifts LDL toward the larger less atherogenic particle size, reduces triglycerides, and improves endothelial function. These interventions are effective, evidence-based, free or low-cost, and carry no side effects. They are systematically deprioritised in the clinical encounter — in part because they generate no revenue.
Before Your Next Appointment
You are not required to be a passive recipient of a prescription. Consider asking: What is my actual absolute risk of a cardiovascular event in the next ten years? How many people with my risk profile need to take this medication for one person to benefit? What lifestyle interventions have been considered, and what is the evidence for them? What are the known risks of this medication, and how should I monitor for them?
A good clinician will welcome these questions. The science in this piece is not hidden. It exists in peer-reviewed journals, Cochrane reviews, and FDA safety communications. It has simply not been reliably translated into the clinical encounter. That gap is something we intend to close.
This article is for educational purposes only and does not constitute medical advice. Do not alter or discontinue any prescribed medication without consulting a qualified healthcare provider. CI Mavericks • Together We Heal.